Analysis of serum microRNA in exosomal vehicles of papillary thyroid cancer

Capriglione, Francesca; Verrienti, Antonella; Celano, Marilena; Maggisano, Valentina; Sponziello, Marialuisa; Pecce, Valeria; Gagliardi, Agnese; Giacomelli, Luciano; Aceti, Valerio; Durante, Cosimo; Bulotta, Stefania; Russo, Diego

doi:10.1007/s12020-021-02847-2

Cited by 14 publications

(11 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Interestingly, the EV-incorporated and serum miRNA profiles were clearly different, suggesting that purified serum-EV miRNA-27a and miRNA-128, rather than bulk serum miRNAs, could be used to diagnose breast cancer with high accuracy. This is in line with other studies indicating a poor correlation between miRNA levels in EVs and the blood [89][90][91]. For instance, Cheng et al demonstrated that miRNA levels differ remarkably between plasma and serum EVs, and between EVs and cell-free plasma and serum [89].…”

Section: Discussionsupporting

confidence: 92%

miRNAs in the Box: Potential Diagnostic Role for Extracellular Vesicle-Packaged miRNA-27a and miRNA-128 in Breast Cancer

Giordano,

Accattatis,

Gelsomino

et al. 2023

IJMS

View full text Add to dashboard Cite

Circulating extracellular vesicle (EV)-derived microRNAs (miRNAs) are now considered the next generation of cancer “theranostic” tools, with strong clinical relevance. Although their potential in breast cancer diagnosis has been widely reported, further studies are still required to address this challenging issue. The present study examined the expression profiles of EV-packaged miRNAs to identify novel miRNA signatures in breast cancer and verified their diagnostic accuracy. Circulating EVs were isolated from healthy controls and breast cancer patients and characterized following the MISEV 2018 guidelines. RNA-sequencing and real-time PCR showed that miRNA-27a and miRNA-128 were significantly down-regulated in patient-derived EVs compared to controls in screening and validation cohorts. Bioinformatics analyses of miRNA-target genes indicated several enriched biological processes/pathways related to breast cancer. Receiver operating characteristic (ROC) curves highlighted the ability of these EV-miRNAs to distinguish breast cancer patients from non-cancer controls. According to other reports, the levels of EV-miRNA-27a and EV-miRNA-128 are not associated with their circulating ones. Finally, evidence from the studies included in our systematic review underscores how the expression of these miRNAs in biofluids is still underinvestigated. Our findings unraveled the role of serum EV-derived miRNA-27a and miRNA-128 in breast cancer, encouraging further investigation of these two miRNAs within EVs towards improved breast cancer detection.

show abstract

Section: Discussionsupporting

confidence: 92%

miRNAs in the Box: Potential Diagnostic Role for Extracellular Vesicle-Packaged miRNA-27a and miRNA-128 in Breast Cancer

Giordano,

Accattatis,

Gelsomino

et al. 2023

IJMS

View full text Add to dashboard Cite

show abstract

“…The above factors may cause bias in results. Many studies con rmed the high variability of the results that analyzed the Ex-miRNAs from different series of thyroid tumors 24 . It is necessary to establish standardization of the pre-analytical and analytical procedures to validate the potential role of exosomal miRNAs as biomarkers for the diagnosis and prognosis of lymphonode metastatic PTCs (mPTC).…”

Section: Discussionmentioning

confidence: 99%

Analysis of plasma exosomal miRNAs in papillary thyroid carcinoma with or without lymph node metastasis

Cao¹,

He²

2023

Preprint

View full text Add to dashboard Cite

Objective: Lymph node metastasis (LNM) is one of the difficulties in the treatment of papillary thyroid carcinoma (PTC). To improve the early detection of PTC LNM and search for novel biomarkers, we carried out plasma-derived exosomal microRNAs studies to identify candidate differentially expressed (DE) exosome-derived miRNAs (Ex- miRNAs) as diagnostic biomarkers in several plasma samples from LNM subjects and patients without LNM. Methods: From January 2022 to October 2022, 10 plasma samples from patients with thyroid papillary carcinoma diagnosed pathologically after surgery were involved. Among them, 6 cases had LNM. Plasma from 4 individuals with no LNM was collected as a control. We extracted exosomes by ultracentrifugation, and Ex-miRNAs were profiled using small RNA next-generation sequencing followed by differential expression analysis. Based on unsupervised hierarchical clustering, the exosomal miRNAs expression profile in patients with LNMwas significantly different from the control group. Results: The results indicated that the levels of exosomal hsa-miR-1226-5p were significantly lower in the LNM group compared with nonmetastatic controls (p-value<0.05), whereas hsa-miR-145-5p, hsa-miR-1226-3p, hsa-miR-4745-5p, hsa-miR-673,5-5p, and hsa-miR-6821-5p were significantly higher in the LNM cases than in lymph node-negative group(p-value＜0.05). Ex-miRNAs cargo was profiled with microarrays followed by bioinformatics analyses. Their predicted target genes involved several cancer-related pathways, including Rap1 signaling pathway, cAMP signaling pathway, Calcium signaling pathway, Hippo signaling pathway, and ECM-receptor interaction (p-value<0.05). Conclusions: Patients with LNM represent unique plasma exosomal miRNA profiles. Some abnormally expressed Ex-miRNAs can be identified as potential biomarkers for predicting PTC LNM.

show abstract

“…No difference could be demonstrated in bulk plasma, and no correlation could be highlighted between abundance in EVs and expression in tissue [ 54 ]. The absence of a relationship between the abundance of most free and encapsulated miRNA in the serum of a patient with thyroid diseases was also reported [ 55 ].…”

Section: Evs In Tcmentioning

confidence: 99%

“…In another study, two other EV-miRNAs, miR-6774-3p and miR-6879-5p, were proposed as biomarkers for the prognosis of LNM in PTC patients [ 57 ]. In the third one, four miRNAs (miR24-3p, miR146a-5p, miR181a-5p and miR382-5p) were identified as differentially secreted in EVs from PTC patients without correlation to the presence of LNM [ 55 ].…”

Section: Evs In Tcmentioning

confidence: 99%

Role of Extracellular Vesicles in Thyroid Physiology and Diseases: Implications for Diagnosis and Treatment

2022

View full text Add to dashboard Cite

Extracellular vesicles are spherical subcellular structures delimited by a lipid bilayer and released by most cells in the human body. They are loaded with a myriad of molecules (i.e., nucleic acids and proteins) depending on their cell of origin and provide the ability to transmit a message to surrounding or distant target cells. In several organs, including the thyroid, abundant recent literature reports that extracellular vesicles are responsible for intercellular communication in physiological and pathological processes, and that their utilization as a potential biomarker of pathological states (i.e., cancer, autoimmune diseases) or as therapeutic delivery vehicles promise clinical options. In this review, we present the current knowledge and understanding regarding the role of extracellular vesicles in developing thyroid diseases and diagnosis.

show abstract

Analysis of serum microRNA in exosomal vehicles of papillary thyroid cancer

Cited by 14 publications

References 43 publications

miRNAs in the Box: Potential Diagnostic Role for Extracellular Vesicle-Packaged miRNA-27a and miRNA-128 in Breast Cancer

miRNAs in the Box: Potential Diagnostic Role for Extracellular Vesicle-Packaged miRNA-27a and miRNA-128 in Breast Cancer

Analysis of plasma exosomal miRNAs in papillary thyroid carcinoma with or without lymph node metastasis

Role of Extracellular Vesicles in Thyroid Physiology and Diseases: Implications for Diagnosis and Treatment

Contact Info

Product

Resources

About